IDEAYA Biosciences, Inc. IDYA
36.69
(0.05)
(0.14%)
as of 25 Sep
- Market cap
- $3.6B
- P/E
- 0.0×
Follow IDYA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(14.15%) | (10.92%) | (14.28%) | (16.22%) | |
| (13.26%) | (10.18%) | (13.14%) | (14.89%) | ||
ROIC |
(44.22%) | (25.96%) | (43.10%) | (36.65%) | |
Return on Tangible Assets |
(21.54%) | (18.45%) | (21.89%) | (22.16%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.19) | (0.83) | (0.99) | (1.24) | |
Free Cash Flow |
(105.39) | (73.47) | (87.93) | (113.87) | |
Capital Expenditures |
(3.14) | (2.37) | (2.00) | (2.21) | |
Piotroski F-Score |
4.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(5.44%) | (4.28%) | (5.34%) | (5.51%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
164.90% | 136.43% | 148.15% | 159.75% | |
Selling, General and Administrative Expense of Revenue |
24.82% | 27.45% | 30.19% | 32.92% | |
Share Based Compensation of Revenue |
19.61% | 19.99% | 22.00% | 23.58% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.63 | 0.61 | 0.64 | |
Depreciation/Fixed assets |
(1.14) | (0.66) | (0.32) | (0.15) | |
Capex/Depreciation |
0.34 | 0.44 | 0.71 | 1.77 | |
Revenue per Share |
2.52 | 2.61 | 2.58 | 2.54 | |
Operating CF per Share |
(1.16) | (0.80) | (0.97) | (1.21) | |
Capex per Share |
(0.04) | (0.03) | (0.02) | (0.02) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(71.97%) | (49.29%) | (61.11%) | (74.75%) |
Columns are period end dates